BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60
This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.